CRISPR: From Discovery To Clinic—And Charting A Path Forward
No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...
EMBO Press5d
A CRISPR-Cas9 screen reveals genetic determinants of the cellular response to decitabine
A temporally resolved CRISPR-Cas9 screen reveals DAC-induced DNA damage drives trans-cell cycle cytotoxicity that depends on ...
pharmaphorum7d
FDA gives go-ahead for CRISPR-based sickle cell disease trial
for beta-thalassemia and sickle cell disease. Although it's a long way from the market, the drug could be one of the first to use the revolutionary CRISPR/Cas9 gene editing technology to correct a ...
Q4 Earnings Surprise Greenlights CRISPR Therapeutics Stock Climb
CRISPR Therapeutics AG (CRSP) stock jumped over 9% this week after delivering strong Q4 2024 results ahead of schedule. The ...
Crispr Therapeutics Q4 Earnings Review: Ignore The Lack Of Revenues, Buy The Future
Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...
TechBullion5d
Unveiling the Power of CRISPR Screening in Modern Genomics
CRISPR technology has radically transformed genetic research, and at the forefront of this transformation is CRISPR screening ...
Sickle Cell Disease News9d
SCD gene-editing therapy Casgevy now being offered at CHLA
With the addition of Casgevy, Children’s Hospital Los Angeles now offers two gene therapies for sickle cell, the first being Lyfgenia.
StockNews12d
3 Genomic Stocks at the Forefront of Precision Medicine
Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...